{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:09:49Z","timestamp":1793185789485,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.nbd.2024.106574","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T22:35:49Z","timestamp":1719095749000},"page":"106574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Neurochemical changes in the progression of Huntington's disease: A meta-analysis of in vivo 1H-MRS studies"],"prefix":"10.1016","volume":"199","author":[{"given":"Yinghua","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imis","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Romanzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2024.106574_bb0005","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/mds.28650","article-title":"Tracking Huntington\u2019s disease progression using motor, functional, cognitive, and imaging markers","volume":"36","author":"Abeyasinghe","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0010","first-page":"31","article-title":"Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy","author":"Adanyeguh","year":"2018","journal-title":"NMR in Biomedicine"},{"key":"10.1016\/j.nbd.2024.106574_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183663","article-title":"Mitochondrial membranes modify mutant huntingtin aggregation","volume":"1863","author":"Adegbuyiro","year":"2021","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.nbd.2024.106574_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108719","article-title":"Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration","volume":"196","author":"Andersen","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106574_bb0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00005072-199704000-00013","article-title":"Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington\u2019s disease--an in situ hybridization study","volume":"56","author":"Arzberger","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2024.106574_bb0030","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1212\/01.wnl.0000311267.63292.6c","article-title":"N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance","volume":"70","author":"Benarroch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106574_bb0035","series-title":"Independent Subgroups within a Study, Introduction to Meta-Analysis","first-page":"217","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.nbd.2024.106574_bb0040","article-title":"Vivo brain GSH: MRS methods and clinical applications","volume":"10","author":"Bottino","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.nbd.2024.106574_bb0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2024.106574_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2024.106574_bb0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1523\/JNEUROSCI.1865-20.2020","article-title":"Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease","volume":"41","author":"Caron","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2024.106574_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134465","article-title":"HdhQ111 mice exhibit tissue specific metabolite profiles that include striatal lipid accumulation","volume":"10","author":"Carroll","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2024.106574_bb0065","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1590\/1414-431X20132332","article-title":"Thalamic metabolic abnormalities in patients with Huntington\u2019s disease measured by magnetic resonance spectroscopy","volume":"46","author":"Casseb","year":"2013","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.nbd.2024.106574_bb0070","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11481-013-9460-x","article-title":"Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain","volume":"8","author":"Chang","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.nbd.2024.106574_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/9781118957813.ch3","article-title":"Computing effect sizes for meta-analysis","author":"Cheung","year":"2015","journal-title":"Meta-Analysis"},{"key":"10.1016\/j.nbd.2024.106574_bb0080","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3389\/fphar.2019.01172","article-title":"Myo-inositol and its derivatives: their emerging role in the treatment of human diseases","volume":"10","author":"Chhetri","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nbd.2024.106574_bb0085","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","article-title":"CGS21680 attenuates symptoms of Huntington\u2019s disease in a transgenic mouse model","volume":"93","author":"Chou","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2024.106574_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197414","article-title":"Investigating the transition of pre-symptomatic to symptomatic Huntington\u2019s disease status based on omics data","volume":"21","author":"Christodoulou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1353-8020(98)00026-1","article-title":"No change in striatal glutamate in Huntington\u2019s disease measured by proton magnetic resonance spectroscopy","volume":"4","author":"Clarke","year":"1998","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0100","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.nbd.2024.106574_bb0105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mito.2023.03.001","article-title":"A comprehensive perspective of Huntington's disease and mitochondrial dysfunction","volume":"70","author":"Dai","year":"2023","journal-title":"Mitochondrion"},{"key":"10.1016\/j.nbd.2024.106574_bb0110","article-title":"Cell rearrangement and oxidant\/antioxidant imbalance in Huntington\u2019s disease","volume":"12","author":"D\u2019Egidio","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.nbd.2024.106574_bb0115","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1212\/WNL.0000000000012969","article-title":"Synaptic damage and its clinical correlates in people with early Huntington disease: a PET study","volume":"98","author":"Delva","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106574_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/nu15092029","article-title":"Cyclitols: from basic understanding to their association with neurodegeneration","volume":"15","author":"Derkaczew","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.nbd.2024.106574_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neuroimage.2011.12.038","article-title":"The neurochemical profile quantified by in vivo 1H NMR spectroscopy","volume":"61","author":"Duarte","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.nbd.2024.106574_bb0130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00213-019-05344-7","article-title":"The potential of (1)H-MRS in CNS drug development","volume":"238","author":"Egerton","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nbd.2024.106574_bb0135","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.nbd.2024.106574_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105933","article-title":"Longitudinal spatial mapping of lipid metabolites reveals pre-symptomatic changes in the hippocampi of Huntington\u2019s disease transgenic mice","volume":"176","author":"Farzana","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106574_bb0145","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.molmed.2023.07.010","article-title":"Oligodendrocyte pathology in Huntington\u2019s disease: from mechanisms to therapeutics","volume":"29","author":"Ferrari Bardile","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.nbd.2024.106574_bb0150","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0006-3002(59)90161-1","article-title":"Biosynthesis of N-acetyl-L-aspartic acid","volume":"33","author":"Goldstein","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2024.106574_bb0155","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/01.wnl.0000257090.01107.2f","article-title":"Decreased frontal choline and neuropsychological performance in preclinical Huntington disease","volume":"68","author":"G\u00f3mez-Ans\u00f3n","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106574_bb0160","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/2211-5463.13285","article-title":"Multiplatform metabolomic analysis of the R6\/2 mouse model of Huntington's disease","volume":"11","author":"Hashimoto","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.nbd.2024.106574_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050717","article-title":"Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease","volume":"7","author":"Heikkinen","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2024.106574_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258486","article-title":"Global Rhes knockout in the Q175 Huntington\u2019s disease mouse model","volume":"16","author":"Heikkinen","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2024.106574_bb0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.nbd.2024.106574_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176117","article-title":"Current methods of magnetic resonance for noninvasive assessment of molecular aspects of Pathoetiology in multiple sclerosis","volume":"21","author":"Hnilicova","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0185","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1212\/WNL.50.5.1357","article-title":"1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers","volume":"50","author":"Jenkins","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106574_bb0190","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1046\/j.1471-4159.2000.0742108.x","article-title":"Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington\u2019s disease mice","volume":"74","author":"Jenkins","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2024.106574_bb0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-4159.2005.03411.x","article-title":"Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington\u2019s disease","volume":"95","author":"Jenkins","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2024.106574_bb0200","doi-asserted-by":"crossref","first-page":"1088124","DOI":"10.3389\/fimmu.2022.1088124","article-title":"Neuroinflammation in Huntington\u2019s disease: from animal models to clinical therapeutics","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nbd.2024.106574_bb0205","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.3693-15.2016","article-title":"Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington\u2019s disease model mice","volume":"36","author":"Jiang","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2024.106574_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241613021","article-title":"From pathogenesis to therapeutics: a review of 150 years of Huntington\u2019s disease research","volume":"24","author":"Jiang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0215","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4103\/1673-5374.360289","article-title":"Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies","volume":"18","author":"Jurcau","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.nbd.2024.106574_bb0220","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2174\/18715273113126660170","article-title":"A friend in need may not be a friend indeed: role of microglia in neurodegenerative diseases","volume":"12","author":"Kaushik","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2024.106574_bb0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hup.693","article-title":"A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders\u2014focus on magnetic resonance spectroscopy (MRS) studies","volume":"20","author":"Kim","year":"2005","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.nbd.2024.106574_bb0230","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.nbd.2024.106574_bb0235","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2020.10.024","article-title":"Global brain volume and N-acetyl-aspartate decline over seven decades of normal aging","volume":"98","author":"Kirov","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2024.106574_bb0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejrad.2008.03.023","article-title":"Measurement sequences for single voxel proton MR spectroscopy","volume":"67","author":"Klose","year":"2008","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.nbd.2024.106574_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105199","article-title":"An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington\u2019s disease","volume":"148","author":"Kong","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106574_bb0250","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","article-title":"Function and therapeutic value of astrocytes in neurological diseases","volume":"21","author":"Lee","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nbd.2024.106574_bb0255","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023)","article-title":"Chapter 5: Collecting data","author":"Li","year":"2023"},{"key":"10.1016\/j.nbd.2024.106574_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4484","article-title":"Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): Experts\u2019 consensus recommendations","volume":"34","author":"Lin","year":"2021","journal-title":"NMR Biomed."},{"key":"10.1016\/j.nbd.2024.106574_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10051077","article-title":"Serum-based biomarkers in neurodegeneration and multiple sclerosis","volume":"10","author":"LoPresti","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.nbd.2024.106574_bb0270","first-page":"2813","article-title":"Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress","volume":"25","author":"Lou","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2024.106574_bb0275","doi-asserted-by":"crossref","first-page":"fcac258","DOI":"10.1093\/braincomms\/fcac258","article-title":"Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease","volume":"4","author":"Lowe","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.nbd.2024.106574_bb0280","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.nbd.2024.106574_bb0285","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12640-019-00053-7","article-title":"Creatine as a Neuroprotector: an actor that can play many parts","volume":"36","author":"Marques","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.nbd.2024.106574_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105411","article-title":"A glimpse of molecular biomarkers in Huntington\u2019s disease","volume":"23","author":"Marti-Martinez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0295","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jns.2007.05.035","article-title":"Is brain lactate increased in Huntington\u2019s disease?","volume":"263","author":"Martin","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0300","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12017-018-8518-6","article-title":"The emerging roles of ferroptosis in Huntington\u2019s disease","volume":"21","author":"Mi","year":"2019","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.nbd.2024.106574_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076051","article-title":"Peripheral biomarkers in manifest and Premanifest Huntington\u2019s disease","volume":"24","author":"Morena","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2022.02.023","article-title":"Associations between prognostic index scores and plasma neurofilament light in Huntington\u2019s disease","volume":"97","author":"Parkin","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104940","article-title":"Functional MRS studies of GABA and glutamate\/Glx - a systematic review and meta-analysis","volume":"144","author":"Pasanta","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.nbd.2024.106574_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.116532","article-title":"Brain GABA and glutamate levels across pain conditions: a systematic literature review and meta-analysis of 1H-MRS studies using the MRS-Q quality assessment tool","volume":"210","author":"Peek","year":"2020","journal-title":"Neuroimage"},{"key":"10.1016\/j.nbd.2024.106574_bb0325","article-title":"Characterization of behavioral, neuropathological, brain metabolic and key molecular changes in zQ175 Knock-in mouse model of Huntington\u2019s disease","volume":"11","author":"Peng","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2024.106574_bb0330","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuroimage.2016.06.023","article-title":"In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease","volume":"139","author":"Pepin","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.nbd.2024.106574_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4301","article-title":"Complementarity of gluCEST and (1) H-MRS for the study of mouse models of Huntington\u2019s disease","volume":"33","author":"Pepin","year":"2020","journal-title":"NMR Biomed."},{"key":"10.1016\/j.nbd.2024.106574_bb0340","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/hmg\/ddy119","article-title":"A whole brain longitudinal study in the YAC128 mouse model of Huntington\u2019s disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes","volume":"27","author":"Petrella","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2024.106574_bb0345","first-page":"15","article-title":"Integrated multi-omics analysis of Huntington disease identifies pathways that modulate protein aggregation","author":"Pradhan","year":"2022","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.nbd.2024.106574_bb0350","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/mrm.21709","article-title":"Myoinositol content in the human brain is modified by transcranial direct current stimulation in a matter of minutes: a 1H-MRS study","volume":"60","author":"Rango","year":"2008","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.nbd.2024.106574_bb0355","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.brainres.2004.10.030","article-title":"Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington\u2019s disease","volume":"1031","author":"Reynolds","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2024.106574_bb0360","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington\u2019s disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0365","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/mds.21601","article-title":"Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy","volume":"22","author":"Ruocco","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0370","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/WNL.53.4.806","article-title":"Clinical correlation of striatal 1H MRS changes in Huntington's disease","volume":"53","author":"S\u00e1nchez-Pernaute","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106574_bb0375","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/JHD-160208","article-title":"Similar progression of morphological and metabolic phenotype in R6\/2 mice with different CAG repeats revealed by in vivo magnetic resonance imaging and spectroscopy","volume":"5","author":"Sawiak","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.nbd.2024.106574_bb0380","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mds.29251","article-title":"Longitudinal clinical and biological characteristics in juvenile-onset Huntington\u2019s disease","volume":"38","author":"Schultz","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuropharm.2018.11.021","article-title":"Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy","volume":"146","author":"Sekar","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106574_bb0390","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.154.8.1148","article-title":"Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder","volume":"154","author":"Shimon","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.nbd.2024.106574_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101503","article-title":"Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer\u2019s disease: a meta-analysis of in vivo magnetic resonance spectroscopy studies","volume":"72","author":"Song","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.nbd.2024.106574_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105147","article-title":"Mitophagy in Huntington\u2019s disease","volume":"149","author":"Sonsky","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.nbd.2024.106574_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13080961","article-title":"The urine metabolome of R6\/2 and zQ175DN Huntington\u2019s disease mouse models","volume":"13","author":"Speziale","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.nbd.2024.106574_bb0410","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.0b013e3181fc27e4","article-title":"Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease","volume":"75","author":"Sturrock","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106574_bb0415","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: the integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2024.106574_bb0420","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mds.870110209","article-title":"Proton magnetic resonance spectroscopy in Huntington\u2019s disease: evidence in favour of the glutamate excitotoxic theory","volume":"11","author":"Taylor-Robinson","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0425","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/mrm.24554","article-title":"Procedure for quantitative (1)H magnetic resonance spectroscopy and tissue characterization of human brain tissue based on the use of quantitative magnetic resonance imaging","volume":"70","author":"Tisell","year":"2013","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.nbd.2024.106574_bb0430","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1471-4159.2006.04323.x","article-title":"Neurochemical changes in Huntington R6\/2 mouse striatum detected by in vivo 1H NMR spectroscopy","volume":"100","author":"Tkac","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2024.106574_bb0435","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/jcbfm.2012.104","article-title":"Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease","volume":"32","author":"Tkac","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nbd.2024.106574_bb0440","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.25010","article-title":"Brain metabolite alterations and cognitive dysfunction in early Huntington\u2019s disease","volume":"27","author":"Unschuld","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2024.106574_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054310","article-title":"Molecular research on Huntington\u2019s disease","volume":"24","author":"Valor","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106574_bb0450","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1097\/00001756-200011270-00032","article-title":"N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice","volume":"11","author":"van Dellen","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2024.106574_bb0455","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1007\/s00415-011-6099-5","article-title":"Exploratory 7-tesla magnetic resonance spectroscopy in Huntington\u2019s disease provides in vivo evidence for impaired energy metabolism","volume":"258","author":"van den Bogaard","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2024.106574_bb0460","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainres.2007.05.082","article-title":"1H magnetic resonance spectroscopy in preclinical Huntington disease","volume":"1168","author":"van Oostrom","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2024.106574_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13040577","article-title":"Multinuclear magnetic resonance spectroscopy at ultra-high-field: assessing human cerebral metabolism in healthy and diseased states","volume":"13","author":"Veeraiah","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.nbd.2024.106574_bb0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40035-021-00278-7","article-title":"Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration","volume":"11","author":"Verma","year":"2022","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.nbd.2024.106574_bb0475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1152\/physrev.00033.2020","article-title":"Calcium-release channels: structure and function of IP(3) receptors and ryanodine receptors","volume":"102","author":"Woll","year":"2022","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.nbd.2024.106574_bb0480","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/jcbfm.2011.157","article-title":"Cortical metabolites as biomarkers in the R6\/2 model of Huntington\u2019s disease","volume":"32","author":"Zacharoff","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nbd.2024.106574_bb0485","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/jnc.15714","article-title":"Neurochemical correlates of synapse density in a Huntington\u2019s disease mouse model","volume":"164","author":"Zarate","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2024.106574_bb0490","article-title":"AMPK-FOXO-IP3R signaling pathway mediates neurological and developmental defects caused by mitochondrial DNA mutations","volume":"120","author":"Zhang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124001748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124001748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T12:28:22Z","timestamp":1738585702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996124001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":98,"alternative-id":["S0969996124001748"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106574","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurochemical changes in the progression of Huntington's disease: A meta-analysis of in vivo 1H-MRS studies","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106574"}}